GlassScriptPhysician profile
George Carrum
NPI 1851471288
$1,777.57
in general payments reported to CMS, 2019-2025
28 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $201 · 2021: $184 · 2022: $23.42 · 2024: $21.51 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $267.63 | 2019-2025 | Breyanzi |
| Astrazeneca Pharmaceuticals LP | $221.29 | 2019-2021 | |
| Janssen Biotech, INC. | $191.17 | 2019-2021 | |
| Amgen INC. | $150.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $111.47 | 2019-2020 | |
| Astellas Pharma US INC | $65.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.35 | 2019 | |
| Dova Pharmaceuticals | $63.67 | 2019 | |
| Kite Pharma, INC. | $60.71 | 2025 | Yescarta |
| Incyte Corporation | $56.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.70 | 2019 | |
| Servier Pharmaceuticals LLC | $49.53 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $49.07 | 2021-2022 | |
| Genzyme Corporation | $46.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.30 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.84 | 2019-2020 | |
| Seagen INC. | $34.16 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $33.48 | 2019 | |
| Rigel Pharmaceuticals, INC. | $32.28 | 2019 | |
| Agios Pharmaceuticals, INC. | $29.21 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.14 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $25.50 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.93 | 2021 | |
| Coherus Oncology, INC. | $21.51 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Carrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.